189 related articles for article (PubMed ID: 9669267)
1. Risks of initiating therapy with sotalol for treatment of atrial fibrillation.
Marcus FI
J Am Coll Cardiol; 1998 Jul; 32(1):177-80. PubMed ID: 9669267
[No Abstract] [Full Text] [Related]
2. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
Chung MK; Schweikert RA; Wilkoff BL; Niebauer MJ; Pinski SL; Trohman RG; Kidwell GA; Jaeger FJ; Morant VA; Miller DP; Tchou PJ
J Am Coll Cardiol; 1998 Jul; 32(1):169-76. PubMed ID: 9669266
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
Hohnloser SH; van de Loo A; Baedeker F
J Am Coll Cardiol; 1995 Oct; 26(4):852-8. PubMed ID: 7560608
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
Joseph AP; Ward MR
Ann Emerg Med; 2000 Jul; 36(1):1-9. PubMed ID: 10874228
[TBL] [Abstract][Full Text] [Related]
5. [The effectiveness and safety of d,l-sotalol in the ambulatory treatment of atrial fibrillation and flutter].
Cruz Cruz F; Iturralde Torres P; Picos Bovio E; Medeiros Domingo A; Infante Vázquez O
Arch Inst Cardiol Mex; 1998; 68(6):482-91. PubMed ID: 10365224
[TBL] [Abstract][Full Text] [Related]
6. Results of sotalol (Darob) therapy in supraventricular tachyarrhythmias.
Toporan D; Protopopescu T; Ioan A; Paraschiv A
Rom J Intern Med; 1998; 36(3-4):207-17. PubMed ID: 10822517
[TBL] [Abstract][Full Text] [Related]
7. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group.
Sung RJ; Tan HL; Karagounis L; Hanyok JJ; Falk R; Platia E; Das G; Hardy SA
Am Heart J; 1995 Apr; 129(4):739-48. PubMed ID: 7900626
[TBL] [Abstract][Full Text] [Related]
8. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG
Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395
[TBL] [Abstract][Full Text] [Related]
9. Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population.
Chandler SF; Chu E; Whitehill RD; Bevilacqua LM; Bezzerides VJ; DeWitt ES; Alexander ME; Abrams DJ; Triedman JK; Walsh EP; Mah DY
Heart Rhythm; 2020 Jun; 17(6):984-990. PubMed ID: 32014568
[TBL] [Abstract][Full Text] [Related]
10. Does Sotalol Still Have a Role in the Management of Arrhythmias?
Semasinghe Bandaralage SP; Nirthanan S; Niranjan S
Am J Ther; 2019; 26(1):e161-e169. PubMed ID: 27759583
[TBL] [Abstract][Full Text] [Related]
11. [Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians].
Patten M; Koch HP; Sonntag F; Lüderitz B; Meinertz T
Z Kardiol; 1999 Mar; 88(3):185-94. PubMed ID: 10355069
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
Rae AP
Am J Cardiol; 1998 Oct; 82(8A):59N-65N. PubMed ID: 9809902
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.
Benditt DG; Williams JH; Jin J; Deering TF; Zucker R; Browne K; Chang-Sing P; Singh BN
Am J Cardiol; 1999 Aug; 84(3):270-7. PubMed ID: 10496434
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacology of modern anti-arrhythmia drugs in therapy of supraventricular tachycardia].
Honerjäger P; Schmidt G
Z Gesamte Inn Med; 1993 Sep; 48(9):425-9. PubMed ID: 8212747
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of supraventricular tachyarrhythmias: drugs or ablation?].
Chimienti M; Barbieri S
G Ital Cardiol; 1996 Feb; 26(2):213-26. PubMed ID: 8666179
[No Abstract] [Full Text] [Related]
16. Management of supraventricular tachyarrhythmias.
Aronow WS
Compr Ther; 1989 Apr; 15(4):11-6. PubMed ID: 2650980
[No Abstract] [Full Text] [Related]
17. Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.
Sahar DI; Reiffel JA; Bigger JT; Squatrito A; Kidwell GA
Am Heart J; 1989 Mar; 117(3):562-8. PubMed ID: 2919535
[TBL] [Abstract][Full Text] [Related]
18. Oral d,l-sotalol in atrial fibrillation and/or flutter.
Cosío FG
Am J Cardiol; 2000 Jan; 85(1):132-3. PubMed ID: 11078258
[No Abstract] [Full Text] [Related]
19. [The treatment of paroxysmal supraventricular arrhythmias in IHD patients with a high risk of developing complications from the anti-arrhythmic therapy].
Andriushchenko OM; Olesin AI
Ter Arkh; 1996; 68(5):57-60. PubMed ID: 9082603
[TBL] [Abstract][Full Text] [Related]
20. [Drug therapy of cardiac arrhythmias 199].
Dietz A; Manz M
Fortschr Med; 1997 Nov; 115(33):32, 34-6, 38. PubMed ID: 9480278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
